The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| Accelerate Diagnostics Inc | COM | 00430H102 | 2,267 | 105,468 | SH | SOLE | 1 | 105,468 | 0 | 0 | |
| Achillion Pharmaceuticals Inc | COM | 00448Q201 | 21,061 | 1,951,922 | SH | SOLE | 1 | 1,951,922 | 0 | 0 | |
| Agenus Inc | COM NEW | 00847G705 | 9,867 | 2,173,267 | SH | SOLE | 1 | 2,173,267 | 0 | 0 | |
| Atara Biotherapeutics Inc. | COM | 046513107 | 11,247 | 425,852 | SH | SOLE | 1 | 425,852 | 0 | 0 | |
| Berkshire Hathaway Inc | CL B NEW | 084670702 | 7 | 50 | SH | SOLE | 1 | 50 | 0 | 0 | |
| Celldex Therapeutics Inc | COM | 15117B103 | 9,806 | 625,386 | SH | SOLE | 1 | 625,386 | 0 | 0 | |
| CytRx Corp | COM PAR $.001 | 232828509 | 1,224 | 461,824 | SH | SOLE | 1 | 461,824 | 0 | 0 | |
| Dicerna Pharmaceuticals Inc | COM | 253031108 | 23,446 | 1,975,229 | SH | SOLE | 1 | 1,975,229 | 0 | 0 | |
| Five Prime Therapeutics Inc | COM | 33830X104 | 10,477 | 252,452 | SH | SOLE | 1 | 252,452 | 0 | 0 | |
| Kite Pharma Inc | COM | 49803L109 | 25,335 | 411,143 | SH | SOLE | 1 | 411,143 | 0 | 0 | |
| Mirati Therapeutics Inc | COM | 60468T105 | 11,954 | 378,287 | SH | SOLE | 1 | 378,287 | 0 | 0 | |
| NVRO 05/20/2016 PUT 50 | COM | 64157F103 | 37 | 142 | SH | Put | SOLE | 1 | 142 | 0 | 0 |
| Omeros Corp | COM | 682143102 | 28,086 | 1,785,502 | SH | SOLE | 1 | 1,785,502 | 0 | 0 | |
| USO 01/15/2016 CALL 25 | Units | 91232N108 | 7 | 13,850 | SH | Call | SOLE | 1 | 13,850 | 0 | 0 |
| VIVO 01/15/2016 CALL 20 | COM | 589584101 | 110 | 1,252 | SH | Call | SOLE | 1 | 1,252 | 0 | 0 |
| Alnylam Pharmaceuticals Inc | COM | 02043Q107 | 52,972 | 562,697 | SH | SOLE | 1 | 562,697 | 0 | 0 | |
| BioCryst Pharmaceuticals Inc | COM | 09058V103 | 20,362 | 1,973,108 | SH | SOLE | 1 | 1,973,108 | 0 | 0 | |
| Bristol-Myers Squibb Co | COM | 110122108 | 7,177 | 104,330 | SH | SOLE | 1 | 104,330 | 0 | 0 | |
| Corium International Inc | COM | 21887L107 | 5,928 | 730,031 | SH | SOLE | 1 | 730,031 | 0 | 0 | |
| Dyax Corp | COM | 26746E103 | 4,275 | 113,641 | SH | SOLE | 1 | 113,641 | 0 | 0 | |
| Global Blood Therapeutics Inc | COM | 37890U108 | 5,080 | 157,115 | SH | SOLE | 1 | 157,115 | 0 | 0 | |
| Invuity Inc | COM NEW | 46187J205 | 44 | 5,000 | SH | SOLE | 1 | 5,000 | 0 | 0 | |
| La Jolla Pharmaceutical Co | COM PAR $.0001 2 | 503459604 | 28,735 | 1,064,247 | SH | SOLE | 1 | 1,064,247 | 0 | 0 | |
| Lipocine Inc | COM | 53630X104 | 2,798 | 216,414 | SH | SOLE | 1 | 216,414 | 0 | 0 | |
| Regenxbio Inc | COM | 75901B107 | 1,972 | 118,771 | SH | SOLE | 1 | 118,771 | 0 | 0 | |
| Symmetry Surgical Inc | COM | 87159G100 | 7,942 | 863,264 | SH | SOLE | 1 | 863,264 | 0 | 0 | |
| Adaptimmune Therapeutics-adr | SPONDS ADR | 00653A107 | 83 | 6,923 | SH | SOLE | 1 | 6,923 | 0 | 0 | |
| Biopharmx Corp | COM | 09072X101 | 563 | 370,636 | SH | SOLE | 1 | 370,636 | 0 | 0 | |
| Global Blood Therapeutics Inc | COM | 37890U108 | 478 | 14,783 | SH | SOLE | 1 | 14,783 | 0 | 0 | |
| Invuity Inc | COM NEW | 46187J205 | 1,745 | 197,808 | SH | SOLE | 1 | 197,808 | 0 | 0 | |
| Nivalis Therapeutics Inc | COM | 65481J109 | 232 | 30,000 | SH | SOLE | 1 | 30,000 | 0 | 0 | |
| Regenxbio Inc | COM | 75901B107 | 1,634 | 98,439 | SH | SOLE | 1 | 98,439 | 0 | 0 | |